行情

AGIO

AGIO

Agios制药
NASDAQ

实时行情|Nasdaq Last Sale

41.08
+0.78
+1.94%
盘后: 41.08 0 0.00% 16:00 08/13 EDT
开盘
40.81
昨收
40.30
最高
41.28
最低
39.93
成交量
98.35万
成交额
--
52周最高
56.75
52周最低
27.77
市值
28.39亿
市盈率(TTM)
-7.7454
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测AGIO价格均价为65.45,最高价位80.00,最低价为40.00。

EPS

AGIO 新闻

更多
Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020
CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the virtual Canac
GlobeNewswire · 08/06 11:00
Agios Pharmaceuticals Inc (AGIO) Q2 2020 Earnings Call Transcript
With me on the call today with prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer; Dr. Chris Bowden, our Chief Medical Officer; Darrin Miles, our Senior Vice President of US Commercial and Global Marketing; and Andrew Hirsch, our Chief Financia
Motley Fool · 07/31 02:01
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 7.75% and 5.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/30 13:55
Agios Pharmaceuticals Earlier Reported Q2 EPS $(1.31) Beats $(1.37) Estimate, Sales $37.35M Miss $37.71M Estimate
Benzinga · 07/30 12:46
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 12:09
Agios Reports Business Highlights and Second Quarter 2020 Financial Results
– Second Quarter TIBSOVO® Net Revenue of $27.6 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million – – Significant Clinical Progress for First-in-Class PKR Activator Mitapivat: Established Proof-of-Concept in Sickle Cell Di
GlobeNewswire · 07/30 11:00
Agios Pharmaceuticals EPS beats by $0.08, beats on revenue
Seeking Alpha · 07/30 04:00
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha · 07/30 04:00

所属板块

生物技术和医学研究
+0.99%
制药与医学研究
-0.06%

热门股票

代码
价格
涨跌幅

AGIO 简况

Agios Pharmaceuticals, Inc.是一家生物制药公司。该公司探索及开发用于治疗癌症及罕见遗传病(罕见遗传代谢疾病)的口服小分子药物。癌症治疗候选产品包括AG-221及AG-120以及AG-881。AG-221及AG-120分别靶向突变型异柠檬酸脱氢酶2及异柠檬酸脱氢酶1(即IDH2及IDH1)。AG-881同时靶向突变型IDH1及突变型IDH2。罕见遗传病计划的主要候选产品AG-348靶向R型丙酮酸激酶。该产品是丙酮酸激酶缺乏症的治疗药物。AG-221是用于治疗癌症的口服选择性突变型IDH2蛋白抑制剂。AG-120是用于治疗癌症的口服选择性突变型IDH1蛋白抑制剂。AG-881是口服的、可穿透脑屏障的选择性泛突变IDH抑制剂。
展开

微牛提供Agios Pharmaceuticals Inc(NASDAQ-AGIO)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的AGIO股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易AGIO股票基本功能。